Having trouble viewing this email? View in your browser.

WEEKLY NEWS

16 January 2024

Save with Early Bird rates for ECCMID 2024 registration

Early Bird Registration ends in less than 1 month! Don't miss out on the lowest prices available to join us in Barcelona this year at ECCMID 2024.

You can also pick up our 40-year anniversary pin during registration with all proceeds going to support child vaccination and water sanitation projects.

IMPORTANT DATES AND DEADLINES

17 January 2024 | Deadline

CAREer Grant applications

.

19 January 2024 | Deadline

Director of Emerging Infections Subcommittee applications

.

24 January 2024 | Deadline

Mayo Clinic Observership applications

.

14 February 2024 | Deadline

ECCMID 2024 Early Bird Registration

Two days left to apply for Director of the Emerging Infections Subcommittee

The call for the new Director of the ESCMID Emerging Infections Subcommittee is open for 2 days only. Don't miss your opportunity to take on a leadership role within ESCMID!


Interested candidates are encouraged to send their applications by
19 January. You can see the full details of the role on the ESCMID website.

Register for this ESCMID online course until 1 February

This course presents and summarises currently available knowledge on PK/PD of commonly used antibiotics, strategies for setting clinical breakpoints, individualised dosing, and therapeutic drug monitoring. The aim is to provide participants with insights that can be used to optimise antibiotic therapy for different patient groups, infection sites and pathogens.

Last day to apply for the ESCMID CAREer Grant

The ESCMID CAREer Grant aims to empower members to overcome career hurdles by providing financial assistance to members who need to reduce their workload or are already working part-time due to family care responsibilities (childcare, illness, care of elderly parents, etc.).


Applications will close tomorrow, 17 January!

The Story Behind the Study - check out another issue

Beyond the lab environments and complex data, there lies a captivating story waiting to be unveiled - a story that speaks of challenges, cooperation, and the pursuit of understanding infection, in order to help patients. The CMI editors hope this story will help you in your career choices.

Update your knowledge on neglected parasitic diseases & malaria with this workshop

Objectives of the workshop:

  • Give an updated view of the clinical, diagnostic and therapeutic aspects of the situation of neglected parasitic diseases
  • Show the capabilities of artificial intelligence in the diagnosis of those diseases
  • Carry out intercomparison work to improve diagnostic systems
  • Transmit and discuss the current problems of the diagnosis of neglected parasitic diseases
  • Debate about the procedures established in the European continent

Tuberculosis treatment monitoring tests during routine practice: study design guidance

Ecraid Training Modules on Adaptive Clinical Trial Designs - A free six-part online course introducing the future of clinical trials featuring leading experts, launches 31 January

The EMA has published for public consultation a "concept paper on the establishment of a guideline on the development and manufacture of human medicinal products specifically designed for phage therapy"

Check out the European Committee on Infection Control (EUCIC) newsletter!

ESCMID Executive Office
Aeschenvorstadt 55
4051 Basel
Switzerland

Phone +41 61 508 0150
info@escmid.org
www.escmid.org

.

The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program's address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.

.
. .